Abeer Alenazi, Deputy Director, PGY2 Hematology/Oncology Pharmacy Residency Program at Prince Sultan Military Medical City, shared a post in LinkedIn:
“The FDA approval of Palbociclib combined with trastuzumab (± pertuzumab) and endocrine therapy for maintenance treatment in HR-positive/HER2-positive metastatic breast cancer is another important step toward chemotherapy de-escalation in selected patients.
The PATINA trial has now established CDK4/6 inhibition as part of the maintenance strategy in this setting. However, the more interesting scientific question is no longer whether to use a CDK4/6 inhibitor…
The real question is:
Are all CDK4/6 inhibitors interchangeable in HER2-positive disease?
While palbociclib is now the first agent to receive regulatory approval in this indication, we cannot automatically assume a class effect.
Although palbociclib, ribociclib, and abemaciclib target the same pathway, they differ in:
- Kinase selectivity
- Pharmacokinetic profiles
- Toxicity patterns
- Dosing schedules
- Clinical evidence across disease settings
Most importantly, regulatory approval follows evidence-not mechanism. Until comparable phase III data become available for other CDK4/6 inhibitors in HER2-positive breast cancer, palbociclib remains the only agent supported by level I evidence in this maintenance setting.
It will be fascinating to see whether future studies demonstrate a true class effect-or whether efficacy will remain molecule-specific. This approval not only changes practice but also opens an important discussion on how we interpret ‘class effects’ in oncology.”
You can also read:
